tbuckley/cabot-search huggingface dataset:
Fludarabine and Cyclophosphamide Based Conditioning Is Associated with Good Outcomes in Patients Undergoing Matched Sibling Donor Transplants for Aplastic Anaemia
Authors: Biju George, Aby Abraham, Anu Korula, Anup Devasia, Kavitha M Lakshmi, Uday Prakash Kulkarni, Fouzia N Abu Backer, Alok Srivastava, Vikram Mathews
Journal: Blood (2019)
Phase II Study of Oral Rigosertib Combined with Azacitidine (AZA) As First Line Therapy in Patients (Pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS)
Authors: Shyamala C. Navada, Guillermo Garcia-Manero, Ehab L. Atallah, M. Nabeel Rajeh, Jamile M. Shammo, Elizabeth A. Griffiths, Samer K. Khaled, Shaker R. Dakhil, David E. Young, Rosalie Odchimar-Reissig, Afoluso Ronnee Adesanya, Patrick S. Zbyszewski, Richard C. Woodman, Pierre Fenaux, Lewis R. Silverman
Journal: Blood (2019)
Whole Exome Sequencing Identifies Candidate Genes Associated with Hereditary Predisposition to Uveal Melanoma
Authors: Mohamed H. Abdel-Rahman, Klarke M. Sample, Robert Pilarski, Tomas Walsh, Timothy Grosel, Daniel Kinnamon, Getachew Boru, James B. Massengill, Lynn Schoenfield, Ben Kelly, David Gordon, Peter Johansson, Meghan J. DeBenedictis, Arun Singh, Silvia Casadei, Frederick H. Davidorf, Peter White, Andrew W. Stacey, James Scarth, Ellie Fewings, Marc Tischkowitz, Mary-Claire King, Nicholas K. Hayward, Colleen M. Cebulla
Journal: Ophthalmology (2019)
Flow Cytometry-Based Pre-Transplant Minimal Residual Disease Detection Strongly Impacts on the Outcome of Haploidentical Transplantation with Αβ T Cell Depletion in Pediatric Acute Lymphoblastic Leukemia
Authors: Larisa Shelikhova, Maria Ilushina, Alexander Popov, Zhanna Shekhovtsova, Dmitriy Balashov, Alexey Kazachenok, Yakov Muzalevsky, Irina Shipitsina, Daria Shasheleva, Rimma Khismatullina, Elena Kurnikova, Sergey Blagov, Julia Abugova, Anna Bogoyavlenskaya, Daria Kobyzeva, Dmitriy Pershin, Yulia Olshanskaya, Alexey Nechesnyuk, Ekaterina Mikhailova, Maria Fadeeva, Natalia Miakova, Dmitry Litvinov, Galina Novichkova, Alexey A. Maschan, Michael Maschan
Journal: Blood (2019)
Preclinical Characterization of an ANTI-CD38/CD3 T CELL-Redirecting Bispecific Antibody
Authors: Xiao He, Yanliang Zhang, Yun Wei Lai, Stephanie Baguley, Yan Li, Xia Cao, Ying Yan, Ken Takeshita, Jerome B. Zeldis, Henry Ji, Gunnar F. Kaufmann
Journal: Blood (2019)
Incidence and outcomes of rare T cell lymphomas from the T Cell Project: hepatosplenic, enteropathy associated and peripheral gamma delta T cell lymphomas
Authors: Francine M. Foss, Steven M. Horwitz, Monica Civallero, Monica Bellei, Luigi Marcheselli, Won Seog Kim, Maria E. Cabrera, Ivan Dlouhy, Arnon Nagler, Ranjana H. Advani, Emanuela A. Pesce, Young‐Hyeh Ko, Silvia Montoto, Carlos Chiattone, Alison Moskowitz, Michele Spina, Marina Cesaretti, Irene Biasoli, Massimo Federico
Journal: American Journal of Hematology (2019)

The T Cell Project was the largest prospective trial to explore the incidence, treatment patterns, and outcomes for T cell lymphomas. The rare subtypes of T cell lymphomas, including hepatosplenic T cell lymphoma (HSTCL), enteropathy associated T cell lymphoma (EATL), and peripheral gamma delta T cell lymphomas (PGDTCLs) are poorly represented in most studies and there is little data regarding treatment patterns. We report results from 115 patients with hepatosplenic (n = 31), enteropathy associated (n = 65), and PGDTCLs (n = 19). While anthracycline regimens were most commonly used as first line therapy, response rates ranged from 20%-40% and were suboptimal for all groups. Autologous stem cell transplantation was performed as a consolidation in first remission in a small number of patients (33% of HSTCL, 7% of EATL, and 12% of PGDTCL), and four patients with HSTCL underwent allogeneic stem cell transplantation in first remission. The progression free survival at 3 years ranged from 28%-40% for these rare subtypes, and the overall survival at 3 years was most favorable for PGDTCL (70%). These data highlight the need for novel treatment approaches for rare subtypes of T cell lymphomas and for their inclusion in clinical trials.
NF-κB-Dependent Activation of the Proteasome Components, PSMD1 and PSMD3, As a Mechanism of Resistance to Imatinib
Authors: Idaly Maria Olivas, Joshua Lara, Rebecca Ellwood, Carme Ripoll Fiol, Andres J Rubio, Alfonso Enrique Bencomo, Mayra Alejandra Gonzalez, Georgios Nteliopoulos, Alistair Reid, Dragana Milojkovic, Jane Apperley, Jamshid Sorouri Khorashad, Anna M. Eiring
Journal: Blood (2019)
RTHP-09. SINGLE INSTITUTION’S EXPERIENCE FOR PEDIATRIC INTRACRANIAL EPENDYMOMA TREATED WITH ADJUVANT RADIOTHERAPY
Authors: Joongyo Lee, Seo Hee Choi, Hong In Yoon, Jeong Woo Han, Ikjae Lee, Dong seok Kim, Chang-Ok Suh
Journal: Neuro-Oncology (2019)

Abstract PURPOSE To investigate long term outcomes of pediatric intracranial ependymoma treated with maximal safe resection followed by radiotherapy in single institution. METHODS Between 1983 and 2016, 42 pediatric patients received adjuvant radiotherapy after surgery. There were 19 and 23 grade II and III ependymomas, and total resection could be performed in 50% of patients. There were 4 patients with initial leptomeningeal seeding, and craniospinal irradiation (CSI) was the component of adjuvant treatment in 5 patients including them. Local radiotherapy (median 54 Gy (range, 45–60 Gy) was performed in all the rest patients excluding three with whole-brain radiotherapy. RESULTS With a median follow-up of 89 months, 14 patients (33%) experienced recurrences after radiotherapy (m/c: intracranial, 79%, all within tumor bed). The 5- and 10-year progression-free survival (PFS) rates were 70% and 63%, and overall survival (OS) rates were 85% and 78%, respectively. The recurrence rates were significantly higher in patients younger than 3 years (64% vs. 23%, p = 0.024) or with subtotal resection (STR) (52% vs. 15%, p = 0.009). In multivariate analyses, age and STR were significant factors for PFS (p = 0.007 and 0.028, respectively). There was no independent prognostic factor for OS on multi-variate analysis. Fourteen patients experienced recurrence. Among them, all of 6 grade II cases showed local recurrence. Four grade II cases (67%) underwent aggressively salvage treatments such as resection, stereotactic radiosurgery were still under observation. However, 75% of 8 grade III recurrent cases were expired, despite aggressive salvage treatments. All 3 patients with seeding recurrent were grade III and died from disease. CONCLUSION Local adjuvant radiotherapy showed favorable survival in pediatric ependymoma. Even if recurrence occurs, aggressive salvage treatment would be needed for grade II ependymoma.
ATIM-04. PHASE I IMMUNOVIROTHERAPY TRIAL OF IL-12 EXPRESSING HSV-1 (M032) IN PET DOGS WITH SPONTANEOUS HIGH GRADE GLIOMAS: A PRELIMINARY REPORT
Authors: M Renee Chambers, David Crossman, Jeremy Foote, Jey Koehler, James Markert, Simon Platt, D Mitchell Self, Andy Shores, Alicia Waters, Amy Yanke, G Yancey Gillespie
Journal: Neuro-Oncology (2019)

Abstract Malignant gliomas are the most common primary brain tumors in humans, accounting for approximately 30% of all primary central nervous system (CNS) tumors in adults. Incidence and outcomes of gliomas in pet dogs are similar to humans. Previous methods of studying gliomas in rodent models do not adequately represent several features that define human cancers, most notably the sporadic nature of tumor development. Murine models lack intra-tumoral heterogeneity or hosts do not have an intact immune system. To overcome these rodent model deficiencies, many investigators have used canine models to study human diseases. We describe a prospective, phase I clinical trial in canine patients with sporadic high-grade gliomas to evaluate M032, a mutant HSV-1 expressing IL-12, alone or combined with a checkpoint inhibitor (Indoximod) to assess safety, tolerability and efficacy. M032 has been shown to infect and kill glioma cells, producing a virus and tumor cell antigen-rich debris field; will provide an increased adjuvant effect from released viral DNA recognized by TLR-9 receptors; and express IL-12 locally, stimulating activation of TH1 lymphocytes. The intratumoral inflammatory cell infiltration is expected to result in immune-related anti-viral responses with cross-epitope spreading to tumor antigens. Indoximod immunomodulation will be tested in latter cohorts to prolong anti-tumor responses. To date, six canines with high-grade gliomas have received intratumoral M032 without virus-related toxicities. Resected tumor and serial blood samples are being cryopreserved for analysis of lymphoid and monocyte/myeloid subset markers. This same virus is being tested in a phase 1 clinical trial in humans with high-grade malignant gliomas; eight human patients have received treatment at this writing without virus-related toxicities. The concurrent prosecution of both trials allows unprecedented real time comparison of safety and efficacy of immunovirotherapy as a stringent test of suitability of the dog as a valid and informative model of human brain tumors.
DRES-01. EFFICACY OF EGFR PLUS TNF INHIBITION IN A PRECLINICAL MODEL OF GLIOBLASTOMA
Authors: Gao Guo, Ke Gong, Jann Sarkaria, Amyn Habib
Journal: Neuro-Oncology (2019)

Abstract EGFR gene amplification and mutation are common in glioblastoma (GBM), but EGFR inhibition is not effective in treating this tumor. EGFR inhibition may fail because EGFR is not a driver of the malignant phenotype in GBM, or because adaptive compensatory mechanisms are triggered by EGFR inhibition that prevent cell death from a loss of EGFR signaling. We have recently identified a TNFα-JNK-Axl-ERK signaling axis that mediates primary resistance to EGFR inhibition in GBM. Temozolomide (TMZ) is the most effective chemotherapy in GBM, although it has only a modest effect on overall survival. The efficacy of TMZ depends on the absence of the DNA repair protein O6-alkylguanine DNA alkyltransferase (MGMT) which reverses the DNA damage induced by TMZ. The MGMT promoter is hypermethylated in about 45% of GBMs, resulting in lack of MGMT expression. TMZ is less effective in MGMT unmethylated GBMs. Moreover, even initially responsive tumors develop a secondary resistance to TMZ. No treatment is effective in recurrent TMZ-resistant GBM. In this study, we compare the efficacy of temozolomide versus EGFR plus TNF inhibition in an orthotopic model of GBM. We find that efficacy of the two treatments is similar in MGMT-methylated GBMs. However, in MGMT-unmethylated GBMs, a combination of EGFR plus TNF inhibition is more effective. We demonstrate that the two treatment approaches target distinct and non-overlapping pathways. Furthermore, and importantly, EGFR plus TNF inhibition remains effective in TMZ-resistant recurrent GBMs and in GBMs rendered experimentally resistant to TMZ. Since the EGFR is expressed in the majority of GBMs, EGFR inhibition combined with a blunting of the accompanying TNF-driven adaptive response could be a broadly applicable and viable therapeutic approach in primary GBMs with MGMT unmethylation and in recurrent GBMs.
COMP-02. MINING-GUIDED MACHINE LEARNING ANALYSES SUPPORTS GRASPING THE LATEST TRENDS ON NEURO-ONCOLOGY
Authors: Taijun Hana, Shota Tanaka, Takahide Nejo, Yosuke Kitagawa, Satoshi Takahashi, Tsukasa Koike, Yoshihiro Kushihara, Erika Yamazawa, Masashi Nomura, Shunsaku Takayanagi, Nobuhito Saito
Journal: Neuro-Oncology (2019)

Abstract The systems that can objectively predict the future trends of a particular research field are always anticipated while conducting medical research. Such systems also provide a considerable aid to researchers while determining and acquiring appropriate research budgets. This study intended to establish a novel and versatile algorithm that can predict the latest trends in neuro-oncology. Seventy-nine neuro-oncological research fields were selected using computational sorting methods, such as text-mining analyses, along with 30 journals that represent the recent trends in the neuro-oncology field. Further, the annual impact (AI) for each year with respect to each journal and field (number of articles published in the journal × the impact factor of the journal) was calculated as a novel concept. Subsequently, the AI index (AII) for the year was defined as the sum of the AIs for the aforementioned 30 journals. With respect to the aforementioned neuro-oncological research fields, the AII trends from 2008 to 2017 were subjected to machine learning predicting analyses. The prediction accuracy of the latest trends in neuro-oncology was validated using actual data obtained from previous studies. In particular, the linear prediction model achieved a relatively good accuracy. The most notable and latest predicted fields in neuro-oncology included some interesting emerging fields, such as microenvironment and anti-mitosis, as well as the already renowned fields, such as immunology and epigenetics. Furthermore, we retrospectively attempted an analysis of the fields different from neuro-oncology. Interestingly, as of 2008, the future emergence of the CRISPR-Cas9 gene editing system has been predicted using this system. Overall, the presented algorithm displays potential to be an effective and versatile tool for the prediction of future trends in a particular medical field.
Alpha-chymotrypsin in Cataract Surgery
Authors: D. Pierse, H. N. O'donoghue
Journal: BMJ (1960)

the older age-groups (in the City of Birmingham survey there were 44,000 women, as opposed to 24,800 men, over the age of 70 years).Both of these factors would operate to produce more ruptures of the heart in women than in men.Although we cannot explain the increased risk of rupture in older patients, we can get some information from the hospital series about the circumstances in which rupture occurs.The maximal risk is in old patients with electrocardiographic evidence of transmural infarction, the first 24 hours after the infarction being particularly critical.There is no evidence to support the view that the patients who rupture are the ones whose blood-pressure remains high after the infarction.The rupture did not relate to physical activity, for most of our patients were in bed, and nearly half were asleep, at the time of rupture.Summary 215 cases of rupture of the heart after myocardial infarction are reported.The sex ratio (96 male; 119 female) differs significantly from that for myocardial infarction.This is due to the increasing risk of ruptur9 in old patients and the tendency for women to develop infarcts later in life than men.The risk of rupture is maximal in the first 24 hours after infarction, and there does not appear to be any correlation with physical activity, digitalis or anti- coagulant treatment, or high blood-pressure levels after infarction.We are grateful to the Records Departments of the United Oxford and the United Birmingham Hospitals for their help with the case-notes, and we are particularly indebted to Mr., G. Billington, H.M. Coroner for the City of Birmingham, for allowing us to make use of his records.
Hotspot U2AF1 Mutations Determine Missplicing Selectivity: Novel Mechanisms Altering Splicing Factors
Authors: Vera Adema, Courtney E Hershberger, Wencke Walter, Cassandra M Kerr, Stephan Hutter, Yasunobu Nagata, Hassan Awada, Sunisa Kongkiatkamon, Christina Snider, Milo Co, Manja Meggendorfer, Aziz Nazha, Hetty E. Carraway, Mikkael A. Sekeres, Francesc Sole, Richard A Padgett, Torsten Haferlach, Jaroslaw P. Maciejewski, Valeria Visconte
Journal: Blood (2019)
Efficacy and Safety of CPX-351 Versus 7+3 in a Phase 3 Exploratory Analysis in Patients with High-Risk/Secondary Acute Myeloid Leukemia (AML) with Prior Hypomethylating Agent Exposure Who Achieved Remission
Authors: Tara L. Lin, Daniel H. Ryan, Ellen K. Ritchie, Stephen A. Strickland, Donna E. Hogge, Scott R. Solomon, Jonathan E. Kolitz, Gary J. Schiller, Matthew J. Wieduwilt, Robert J. Ryan, Stefan Faderl, Jorge E. Cortes
Journal: Blood (2019)
DRES-12. QUANTIFYING INDIVIDUALIZED ABT-414 SENSITIVITY AND BLOOD-BRAIN BARRIER PENETRANCE FROM SERIAL IMAGING OF PATIENT-DERIVED XENOGRAFTS MODELS OF GLIOBLASTOMA
Authors: Javier Urcuyo, Susan Christine Massey, Bianca-Maria Marin, Jann Sarkaria, Kristin Swanson
Journal: Neuro-Oncology (2019)

Abstract INTRODUCTION Glioblastoma (GBM) is an aggressive primary brain tumor, known for its poor prognosis. Due to its diffuse invasiveness into normal-appearing brain, localized treatments such as surgical resection and radiotherapy are typically supplemented with chemotherapy. However, to reach invading tumor cells, such antineoplastic drugs must cross the blood-brain barrier (BBB). That is, while angiogenesis induces BBB breakdown in dense tumor regions, the BBB remains rather intact for invading GBM cells. As a result, it is unclear whether BBB-impermeable drugs are delivered at a sufficient level to be effective. METHODS In order to study heterogeneity in BBB breakdown, experiments were conducted using both flank and intracranial patient-derived xenografts (PDXs) treated with the EGFR-targeted monoclonal antibody drug conjugate, depatuxizumab mafodotin (ABT-414). Time-series bioluminescence imaging (BLI) data was used to develop a differential equation model of tumor growth for three PDX cell lines. Data from untreated PDXs, both in flank and intracranially, were used to parameterize tumor proliferation rates. Flank PDX data were used to parameterize individual sensitivity to ABT-414, whereas intracranial PDX data were used to determine the proportion of drug exposed to the tumor. RESULTS Each PDX line differed in response to the study drug ABT-414. As expected, such heterogeneous responses can primarily be attributed to differences in both drug sensitivity and the proportion of drug that reached the tumor. Notably, the estimated proportion of drug that reached the tumor was highest in the PDX line with the longest survival times, despite also having higher estimates of resistance. This suggests that PDXs with greater overall BBB breakdown may respond better to this agent. CONCLUSIONS Although more cell lines are needed to validate our approach, parameterizing this model for PDXs gives valuable insight into the extent of BBB breakdown in patient GBMs and may aid in determining optimal therapies for individual patients.
EXTH-01. A SYNGENIC MOUSE MODEL TO STUDY THE EFFICACY OF KETOGENIC DIET IN HIGH GRADE GLIOMAS
Authors: Andrea Salmaggi, Chiara Vasco, Ambra Rizzo, Francesco Padelli, Ileana Zucca, Serena Pellegatta, Giorgio Massa, Laura Fariselli, Mariagrazia Bruzzone, Emilio Ciusani
Journal: Neuro-Oncology (2019)

Abstract Glioblastoma multiforme is the most malignant subtype of brain tumor. Despite multimodal treatment (surgical resection and chemo/radiotherapy) the prognosis remains unsatisfactory. Based on the Warburg hypothesis, ketogenic diet (KD) has been suggested in the treatment of GBM. The syngenic, orthotopic GL261 mouse glioma model was used to evaluate the effects of KD on 7T magnetic resonance imaging/spectroscopy and metabolic response of the tumor to diet. Mice were injected with 10^5 GL261 cells into the caudate nucleus. Following implantation, animals were fed standard chow for five days then were randomly assigned to standard diet or ketogenic diet. 18 days after diet start, mice fed at KD displayed significantly higher plasmatic levels of ketone bodies. Mice fed with KD survived longer than those fed with standard diet (p&lt; 0.05). Decreased concentrations of gamma-aminobutyric acid, N Acetyl Aspartate and N-acetylaspartylglutamate were found in tumor tissue after 9 days from the beginning of the KD diet while a huge increase in beta-hydroxybutyrate (bHB) was detected in tumor tissue as compared to normal brain. The addition of bHB at various concentrations to low-glucose culture medium did not significantly improve GL261 in vitro growth suggesting that this cell line has a limited ability to use bHB as a carbon source. The accumulation of bHB in the tumor tissue in KD fed mice, may suggest either elevated uptake of/release of bHB by tumor cells or inability of tumor cells in this context to use it in mitochondrial metabolism; the latter hypothesis is supported by the observation that GL261 cells did not display an increase in in vitro proliferation when exposed to bHB. The far less evident peak of bHB at MRI spectroscopy in the healthy brain tissue of KD fed mice, on the other hand suggests that normal brain is able to use bHB as energy source.
Comparison of Overall Survival in High Risk Patients with Minimal Residual Disease after First-Line Treatment across Three Generations of Phase 3 Trials of the German CLL Study Group
Authors: Anna Maria Fink, Can Zhang, Sandra Robrecht, Nadine Kutsch, Moritz Fürstenau, Clemens-Martin Wendtner, Karl-Anton Kreuzer, Michael Kneba, Eugen Tausch, Stephan Stilgenbauer, Matthias Ritgen, Sebastian Böttcher, Kirsten Fischer, Michael Hallek, Barbara F. Eichhorst
Journal: Blood (2019)
CD19 CAR T-Cell Therapy in Patients with Relapse/Refractory DLBCL: Retrospective Analysis of the Eligibility Criteria
Authors: Jérôme Paillassa, Roberta Di Blasi, Sylvie Chevret, Sophie Bernard, Michael Darmon, Veronique Meignin, Bénédicte Deau-Fischer, Vincent Camus, Rene-Olivier Casasnovas, Guillaume Cartron, Driss Chaoui, Vincent Delwail, Pierre Feugier, Luc Mathieu Fornecker, Emmanuel Gyan, Corinne Haioun, Frederique Kuhnowski, Jean Valère Malfuson, Jean-Pierre Marolleau, Veronique Morel, Gandhi Damaj, Anne Quinquenel, Sophie Rigaudeau, Celia Salanoubat, Géraldine Salmeron, David Sibon, Elie Azoulay, Maxime Berquier, Catherine Thieblemont
Journal: Blood (2019)
The Broad Spectrum of TP53 Variants in CLL: NGS Analysis of 573 Pathogenic TP53 Variants
Authors: Gregory Lazarian, Floriane Theves, Myriam Hormi, Virginie Eclache, Stéphanie Poulain, Audrey Bidet, Cedric Pastoret, Lauren Veronese, Eric Delabesse, Marie-Hélène Estienne, Nathalie Nadal, Frederic Davi, Florence Nguyen-Khac, Laurence Lode, Pierre Sujobert, Dina Naguib, Sophie Raynaud, Stephane Giraudier, Olivier Kosmider, Pascaline Etancelin, Pascale Cornillet-Lefebvre, Laurent Miguet, Veronique Leblond, Remi Letestu, Thierry Soussi, Florence Cymbalista, Fanny Baran-Marszak
Journal: Blood (2019)
Thirty-Day Transfusion and G-CSF Requirement after CD19 CAR T Infusion
Authors: Jingmei Hsu, Usama Gergis, Tsiporah B. Shore, Sebastian Mayer, Adrienne A. Phillips, Danielle Guarneri, Maria Baldo, Ljiljana V. Vasovic, Yen-Michael S. Hsu, Robert Andrew Desimone, Melissa M. Cushing, Koen Van Besien
Journal: Blood (2019)
Area-Based Socioeconomic Disparities in Survival of Children with Newly Diagnosed Acute Myeloid Leukemia: A Report from the Children's Oncology Group
Authors: Lena E. Winestone, Kelly D Getz, Kira O Bona, Brian T. Fisher, Alan S Gamis, Alix E. Seif, Lillian Sung, Yi-Cheng Wang, Todd A. Alonzo, Richard Aplenc
Journal: Blood (2019)
Mutational Type and Configuration of an Individual Gene May Differentially Impact the Clinical and Phenotypic Features
Authors: Yasunobu Nagata, Hideki Makishima, Cassandra M Kerr, Bhumika J. Patel, Hassan Awada, Vera Adema, Valeria Visconte, Sudipto Mukherjee, Thomas Laframboise, Aziz Nazha, Tomas Radivoyevitch, Mikkael A. Sekeres, Seishi Ogawa, Jaroslaw P. Maciejewski
Journal: Blood (2019)
Efficacy and Safety Outcomes in the Phase 3 INO-Vate Trial By Baseline CD22 Positivity Assessed By Local Laboratories
Authors: Hagop M. Kantarjian, Wendy Stock, Ryan D. Cassaday, Daniel J. DeAngelo, Elias Jabbour, Susan M. O'Brien, Matthias Stelljes, Tao Wang, M. Luisa Paccagnella, Kevin Nguyen, Barbara Sleight, Erik R. Vandendries, Alexander Neuhof, A. Douglas Laird, Anjali S. Advani
Journal: Blood (2019)
Low Suvmax Measured on Baseline FDG-PET/CT and Elevated β2 Microglobulin Are Negative Predictors of Outcome in High Tumor Burden Follicular Lymphoma Treated By Immunochemotherapy: A Pooled Analysis of Three Prospective Studies
Authors: Anne Ségolène Cottereau, Annibale Versari, Loïc Chartier, Jehan Dupuis, Vittoria Tarantino, Rene-Olivier Casasnovas, Antonella Franceschetto, Emmanuel Itti, Hervé Tilly, Corinne Haioun, Massimo Federico, Alina Berriolo, Gilles Andre Salles, Stefano Luminari, Michel Meignan, Judith Trotman
Journal: Blood (2016)